ReviewBritish journal of cancer2020
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
Review in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.The Cochrane database of systematic reviews · 2024Pooled it
- Pooled it
- Complete Response to Tislelizumab in an Elderly Patient With Metastatic Pulmonary Squamous Cell Carcinoma: Potential Synergy With Metformin and Multidisciplinary Management.Clinical case reports · 2026Article
- Efficacy and Safety of Initial Low-Dose, Extended-Interval Nivolumab Monotherapy in a 91-Year-Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report.Clinical case reports · 2026Article
- Correlation between Cx37 and ALK expression and prognosis of elderly patients with non-small cell lung cancer.Journal of cardiothoracic surgery · 2026Article
- Efficacy and safety of immunotherapy in elderly patients with advanced non-small cell lung cancer: a real-world study stratified by age.BMC geriatrics · 2026Article
- Efficacy and safety of nab-paclitaxel plus PD-1 inhibitor in elderly patients with advanced squamous lung cancer.BMC cancer · 2026Article
- Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.BMC cancer · 2025Article
- Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.BMC cancer · 2025Article
- Immunotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: Challenges and Perspectives.International journal of molecular sciences · 2025Review
- Single-Cell and Bulk Transcriptomics Reveal the Immunosenescence Signature for Prognosis and Immunotherapy in Lung Cancer.Cancers · 2024Article
- Review
- Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol.The Cochrane database of systematic reviews · 2024Article
- Review
- Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer.Frontiers in oncology · 2024Review
- Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice.Journal of the National Cancer Institute · 2023Article
- Guidance for Treating the Older Adults with Colorectal Cancer.Current treatment options in oncology · 2023Review
- Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.BMC cancer · 2023Article
- Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.Current oncology (Toronto, Ont.) · 2023Review
- The impact of concurrent bacterial lung infection on immunotherapy in patients with non-small cell lung cancer: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer (NSCLC) from locally advanced disease to the metastatic setting. This approach has resulted in improved survival and a more favourable toxicity profile when compared with chemotherapy. Following the successful introduction of single-agent immunotherapy, current clinical trials are focusing on combination treatments with chemotherapy or radiotherapy or even other immunotherapeutic agents. However, most of the data available from these trials are derived from, and therefore might be more applicable to younger and fitter patients rather than older and often frail lung cancer real-world patients. This article provides a detailed review of these immunotherapy agents with a focus on the data available regarding older NSCLC patients and makes recommendations to fill evidence gaps in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.